{"a":[{"_":"Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS","$":{"href":"/biotech/roche-orchestrates-phase-3-kras-lung-cancer-win-over-amgen-and-bristol-myers","hreflang":"en"}}]}
Phase 3positivedivarasibLumakrasKrazatiPositive
AI Analysis
Summary
Roche's investigational KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competitors Amgen's Lumakras and Bristol Myers Squibb's Krazati in a phase 3 trial, positioning it as a potential new standard of care for KRAS-mutant lung cancer.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Roche's divarasib beat Amgen's Lumakras and Bristol Myers Squibb's Krazati in phase 3 trial
Importance:8/10
Sentiment:
0.80
KRASoncologyphase 3competitive winlung cancer
Read the original article
Published by FierceBiotech on July 2, 2026 5:16 AM